IDL Biotech AB continues preparations to introduce its rapid test for bladder cancer, UBC Rapid, in the US. | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Latest News

September 2019

IDL Biotech AB continues preparations to introduce its rapid test for bladder cancer, UBC Rapid, in the US.

IDL Biotech has started the work on mapping the US market.

Read more here 

IDL Biotech signs distributor agreement in Ghana

IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with Res Health Consult Ltd covering Ghana. The agreement covers the sale of TUBEX® TF.

IDL Biotech includes additional clinics in its ongoing multicenter study for UBC® Rapid in Sweden.

IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder cancer who are classified as high risk.

IDL Biotech

Skip this intro